
Shares of biotech firm ImmunoPrecise Antibodies IPA.O rise ~42% to 69 cents
IPA says it has developed a new class of GLP-1 therapies using AI to improve diabetes treatment
IPA's proprietary tech, called LENSai, uses patterns in biological data to create novel genetic sequences for GLP-1-like constructs
Co says it is investigating transdermal delivery of these therapies as a non-invasive alternative to injections
More than 300 mln shares traded, 708x times their 25-day moving avg
IPA fell ~76% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))